Eswar Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 28-06-2024
- Paid Up Capital ₹ 0.10 M
as on 28-06-2024
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.71 Cr
as on 28-06-2024
- Satisfied Charges ₹ 1.69 Cr
as on 28-06-2024
- Revenue 34.99%
(FY 2023)
- Profit 73.24%
(FY 2023)
- Ebitda 43.10%
(FY 2023)
- Net Worth 54.36%
(FY 2023)
- Total Assets 32.98%
(FY 2023)
About Eswar Therapeutics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.71 Cr. The company has closed loans amounting to ₹1.69 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vikram Khungar, Raj Khurana, and Kashmiri Khunger serve as directors at the Company.
- CIN/LLPIN
U24304CH2017PTC041467
- Company No.
041467
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Apr 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Eswar Therapeutics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikram Khungar  | Director | 25-Jan-2019 | Current |
| Raj Khurana | Director | 01-Apr-2023 | Current |
| Kashmiri Khunger | Additional Director | 16-Apr-2024 | Current |
Financial Performance and Corporate Structure Insights of Eswar Therapeutics.
Eswar Therapeutics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 34.99% increase. The company also saw a substantial improvement in profitability, with a 73.24% increase in profit. The company's net worth Soared by an impressive increase of 54.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eswar Therapeutics?
Unlock access to Eswar Therapeutics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 16 Dec 2023 | ₹0.77 M | Open |
Hdfc Bank Limited Creation Date: 19 Aug 2023 | ₹0.37 M | Open |
Hdfc Bank Limited Creation Date: 19 Aug 2023 | ₹0.37 M | Open |
How Many Employees Work at Eswar Therapeutics?
Eswar Therapeutics has a workforce of 113 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eswar Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eswar Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
